Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Visa

With the coveted trillion-dollar valuation, a new pinnacle of success is approaching for a limited number of companies. This once-impossible milestone is now within reach for three formidable potential trillion-dollar stocks.

3 Stocks Primed to Reach Trillion-Dollar Valuation

Its core therapeutic area will be a major tailwind in the next five years. The drugmaker should make significant progress in other fields, too.

Where Will Eli Lilly Be in 5 Years?

Novo Nordisk

U.S.-based Eli Lilly and Denmark's Novo Nordisk have struck gold with their weight-loss drugs, sending their shares to stratospheric levels and putting them on par with some high-growth tech stocks.

Eli Lilly, Novo Nordisk get growth stock status on weight-loss drug boost

Eli Lilly's one-two punch of weight-loss and diabetes treatments Zepbound and Mounjaro should drive the biopharma stock much higher, said a Morgan Stanley analyst.

Will Weight-Loss, Diabetes Drugs Drive LLY Stock Into $1 Trillion Club?

Morgan Stanley analyst Terence Flynn increases his price target on shares of the drugmaker to $950 from $805.

Eli Lilly Stock's Upside Prompts Morgan Stanley to Ask if It Can Reach $1 Trillion

JPMorgan Chase & Co

A year ago, we wouldn't discuss replacing Tesla (NASDAQ: TSLA ) as one of the Magnificent 7 stocks. However, losing 50% of its value since November, the drum beat gets louder to replace Elon Musk's baby.

My Top 3 Stock Candidates to Replace Tesla in the Magnificent 7

Broadcom

Tesla

Taiwan Semiconductor Manufacturing

Finding the next trillion-dollar companies isn't easy, but it doesn't have to be difficult. While tempting, avoid the urge to pick a handful of small-cap tech stocks or growth stocks that you think may be worth $1 trillion or more in the future.

Meet the Next Trillion-Dollar Companies: Our Top 7 Picks

Amazon

DoorDash

DexCom

FleetCor Technologies

Alphabet

JD.com

Lam Research

Microsoft

NVIDIA

Pinduoduo Inc - ADR

Uber

Tiger Global has slashed its positions in four of the five Magnificent Seven tech stocks that account for almost half of its portfolio, while upping its stake in Amazon.com and piling into semiconductor companies, regulatory filings for the final three months of 2023 show.

Tiger Global slashes stakes in Magnificent Seven while piling into semiconductor makers

Amgen

AstraZeneca

Pfizer

Viking Therapeutics

It is entirely fair to state that weight loss treatments have massive transformational power. US FDA approval of weight loss medicines could help shrink millions of waistlines.

7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution

Eli Lilly's Mounjaro drug is being launched in Britain this week, two pharmacy companies said on Wednesday, making the UK the fourth European country to introduce the highly-anticipated obesity drug.

Britain sees launch of Lilly's weight-loss drug Mounjaro

1-800-FLOWERS.COM

Hershey

1-800-Flowers.com operates a go-to site for sending flowers and other gifts. Hershey is an especially good pick for income investors with its attractive dividend.

3 Perfect Stocks to Buy This Valentine's Day

Amgen is the latest big pharma to join the gold rush to treat obesity. Its candidate is distinct from the medicines by Eli Lilly and Novo Nordisk.

Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?

BioAge Labs, a biotech startup collaborating with Eli Lilly for trialing its obesity therapy, said on Tuesday it had raised $170 million in its latest funding round.

Eli Lilly partner BioAge raises $170 mln for obesity treatment

Eli Lilly and Novo Nordisk stocks have soared, thanks largely to their weight-loss drugs. However, analysts think that another big pharma stock will perform much better over the near term.

Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.

Bristol-Myers

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Johnson & Johnson

Merck

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Q4 Earnings

Eli Lilly's tirzepatide reported positive phase 2 results in treating a severe disease. The drugmaker may well ride the wave of tirzepatide's successes for a long time.

This Unstoppable Growth Stock Just Announced More Good News: Is It a Buy?

American Express

Bath and Body Works

Best Buy

Blackstone Group

Salesforce

General Electric

Kinder Morgan

Kroger

Moderna

Marathon Oil

Whirlpool

Hedge funds with long/short strategies have benefited in 2024 from a macroeconomic environment that has hit the most heavily shorted stocks particularly hard compared to their less shorted rivals, a new UBS report says.

Short sellers boosted by ‘Hedge Fund Nirvana' that sees most heavily-shorted companies suffer

Eli Lilly's weight loss drug Zepbound generated more than $175 million in just its first few weeks on the market. The company is addressing a market that could reach $100 billion by 2030, Goldman Sachs research shows.

Could Eli Lilly's Zepbound Become the World's Best-Selling Drug?

A clinical trial for one of Eli Lilly's gene therapy candidates for hearing loss just reported good data. Even if it gets approved eventually, it might not make much money.

Eli Lilly Just Succeeded Where Others Failed, but Does It Matter for the Stock?

Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.

Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that

Vertex Pharmaceuticals

Eli Lilly has major catalysts ahead. Novo Nordisk delivered strong growth in 2023 and could top that performance in 2024.

3 Stocks That Could Trounce the Market in 2024

Eli Lilly just reported strong Q4 earnings. The stock is soaring due to the growth of its weight loss drugs.

News for Eli Lilly Stock (LLY)